Barclays Cuts IQVIA (NYSE:IQV) Price Target to $235.00

IQVIA (NYSE:IQV) had its target price cut by Barclays from $255.00 to $235.00 in a research note released on Monday,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

IQV has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft cut their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Evercore ISI decreased their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. TD Cowen reduced their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Redburn Atlantic began coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price on the stock. Finally, The Goldman Sachs Group decreased their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $254.53.

IQVIA Stock Up 2.5 %

NYSE IQV opened at $205.12 on Monday. The company has a market capitalization of $37.23 billion, a P/E ratio of 26.92, a PEG ratio of 2.15 and a beta of 1.48. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company’s 50 day simple moving average is $200.29 and its 200 day simple moving average is $219.97.

Institutional Trading of IQVIA

A number of institutional investors have recently added to or reduced their stakes in IQV. FMR LLC lifted its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of IQVIA in the third quarter worth about $147,683,000. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, KBC Group NV lifted its holdings in IQVIA by 68.5% in the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after purchasing an additional 250,458 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.